Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

[1]  A. Go,et al.  Fibroblast growth factor-23 and cardiovascular events in CKD. , 2014, Journal of the American Society of Nephrology : JASN.

[2]  D. Fliser,et al.  FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock , 2013, European heart journal. Acute cardiovascular care.

[3]  Robert J. Vincent,et al.  FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. , 2013, American journal of physiology. Endocrinology and metabolism.

[4]  E. Ingelsson,et al.  Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. , 2013, Kidney international.

[5]  M. Pencina,et al.  Interpreting incremental value of markers added to risk prediction models. , 2012, American journal of epidemiology.

[6]  B. Dai,et al.  A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model , 2012, PloS one.

[7]  B. Kestenbaum,et al.  Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-living Individuals Chs (cardiovascular Health Study) , 2022 .

[8]  T. Szekeres,et al.  Inorganic phosphate and FGF‐23 predict outcome in stable systolic heart failure , 2012, European journal of clinical investigation.

[9]  S. Moe.  Klotho: a master regulator of cardiovascular disease? , 2012, Circulation.

[10]  L. Hsiao,et al.  Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23 , 2012, Circulation.

[11]  S. Solomon,et al.  Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease , 2012, Circulation.

[12]  D. Fliser,et al.  The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. , 2011, European heart journal.

[13]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[14]  G. Navis,et al.  Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[15]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[16]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[17]  E. Rimm,et al.  Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. , 2011, American heart journal.

[18]  A. Hayen,et al.  Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. , 2011, JAMA.

[19]  M. Wolf,et al.  Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease , 2010, Current opinion in nephrology and hypertension.

[20]  L. Schurgers,et al.  The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.

[21]  T. Larsson.  The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  M. Shlipak,et al.  Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  M. Pfeffer,et al.  A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.

[24]  H. Melhus,et al.  Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. , 2009, Atherosclerosis.

[25]  Thomas J. Wang,et al.  Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease , 2009, Circulation.

[26]  M. Wolf,et al.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. , 2008, The New England journal of medicine.

[27]  S. Solomon,et al.  Influence of Albuminuria on Cardiovascular Risk in Patients With Stable Coronary Artery Disease , 2007, Circulation.

[28]  F. Kronenberg,et al.  Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. , 2007, Journal of the American Society of Nephrology : JASN.

[29]  M. Pfeffer,et al.  Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.

[30]  M. Pfeffer,et al.  Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.

[31]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[32]  S. Solomon,et al.  Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial , 2006, Circulation.

[33]  S. Solomon,et al.  Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction: The Survival And Ventricular Enlargement (SAVE) Study , 2004, Circulation.

[34]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[35]  H. Jüppner,et al.  Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. , 2003, Kidney international.

[36]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[37]  K. White,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[38]  E. Nabel,et al.  Angiotensin-converting enzyme 2--a new cardiac regulator. , 2002, The New England journal of medicine.

[39]  Nancy R Cook,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. , 2002, The New England journal of medicine.

[40]  E. Uhlmann,et al.  Reference intervals for plasma cystatin C in healthy volunteers and renal patients, as measured by the Dade Behring BN II System, and correlation with creatinine. , 2001, Clinical Chemistry.

[41]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[42]  M. Pfeffer,et al.  Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. , 1998, The American journal of cardiology.

[43]  Tadashi Kaname,et al.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing , 1997, Nature.

[44]  R. Fandrich,et al.  Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. , 1995, The American journal of physiology.